The Food and Drug Administration’s approval in 2023 of lecanemab — a novel Alzheimer’s therapy shown in clinical trials to modestly slow disease progression — was met with enthusiasm by many in the field as it represented the first medication…
The Food and Drug Administration’s approval in 2023 of lecanemab — a novel Alzheimer’s therapy shown in clinical trials to modestly slow disease progression — was met with enthusiasm by many in the field as it represented the first medication…